Valuation: Nexstim Oyj

Market Cap 8.14Cr 9.31Cr 7.51Cr 6.92Cr 13Cr 896.95Cr 13Cr 90Cr 35Cr 439.29Cr 35Cr 34Cr 1.51TCr P/E 2026 *
84x
P/E 2027 * 37.3x
Enterprise Value 7.93Cr 9.07Cr 7.32Cr 6.74Cr 13Cr 873.81Cr 13Cr 87Cr 34Cr 427.95Cr 34Cr 33Cr 1.47TCr EV / Sales 2026 *
6.24x
EV / Sales 2027 * 4.83x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 11/02/2020
Director of Finance/CFO 40 11/02/2020
Chief Tech/Sci/R&D Officer 65 01/01/2008
Director TitleAgeSince
Director/Board Member 64 11/11/2019
Chairman 63 11/11/2019
Director/Board Member 55 01/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%-5.73% - - 9.31Cr
-1.97%+1.03%+28.39%+1.68% 20TCr
-0.58%+2.40%+7.25%-15.35% 14TCr
-14.15%-15.08%-33.40%-2.68% 12TCr
-1.32%-1.65%-57.52%-16.63% 6.54TCr
-2.40%-7.03%+12.08%-6.81% 4.94TCr
-0.11%+1.53%-23.83%-30.51% 4.47TCr
-3.41%-2.11%+15.33%+9.95% 3.71TCr
-2.44%-1.98%+28.33%+35.71% 3.62TCr
-1.86%-2.39%-22.85%-10.01% 2.87TCr
Average -3.51%-2.32%-5.14%-3.85% 8.07TCr
Weighted average by Cap. -3.70%-1.84%-0.99%-4.99%

Financials

2026 *2027 *
Net sales 1.27Cr 1.45Cr 1.17Cr 1.08Cr 2.04Cr 139.95Cr 2.08Cr 14Cr 5.51Cr 69Cr 5.46Cr 5.34Cr 235.95Cr 1.61Cr 1.84Cr 1.49Cr 1.37Cr 2.58Cr 177.42Cr 2.64Cr 18Cr 6.98Cr 87Cr 6.92Cr 6.77Cr 299.12Cr
Net income 10L 11.44L 9L 9L 16.03L 11Cr 16.39L 1.1Cr 43.38L 5.4Cr 42.97L 42.03L 19Cr 22L 25.17L 20.3L 18.71L 35.27L 24Cr 36.05L 2.43Cr 95.44L 12Cr 94.54L 92.47L 41Cr
Net Debt -21L -24.03L -19.38L -17.86L -33.67L -23Cr -34.41L -2.32Cr -91.1L -11Cr -90.25L -88.27L -39Cr -37L -42.34L -34.14L -31.47L -59.32L -41Cr -60.63L -4.08Cr -1.61Cr -20Cr -1.59Cr -1.56Cr -69Cr
Logo Nexstim Oyj
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-